MEDBOX | Toolbox Vaccine Candidates & Research

Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm, 7 May 2021

World Health Organization WHO (2021) C_WHO

7 May 2021

Tags: sinopharm, vaccine, COVID-19, SARS-CoV-2, vaccine candidates, inactivated vaccines,

Source: https://apps.who.int/iris/rest/bitstream

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (Arabic)

World Health Organization WHO (2021) C_WHO

Interim guidance, 7 May 2021

Tags: sinopharm, vaccine, COVID-19, SARS-CoV-2, vaccine candidates, inactivated vaccines,

Source: https://apps.who.int/iris/bitstream/hand

Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables

World Health Organization WHO (2021) C_WHO

1 June 2021

Tags: sinovac, COVID-19, vaccine, SARS-CoV-2,

Source: https://apps.who.int/iris/rest/bitstream

Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

CDC (2021) CC

These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older

Tags: vaccine, Moderna, COVID-19,

Source: https://www.cdc.gov/vaccines/covid-19/in

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks

Tags: Astra Zeneca, vaccine, vaccine candidates, side effects, clinical trials, COVID-19, SARS-CoV-2,

Source: https://www.who.int/docs/default-source/

Mauder, S. (2021) CC

Issue Brief no.8. January 18,2021 Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies, implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages

Tags: Vaccination, Access, strategy, Immunization, Guidelines, global initiatives, vaccine candidates, research, vaccine trial, resources,

Source: https://medbox.org/document/covid-19-vac

Organisation Mondiale de la Santé OMS (2021) C_WHO

10 février 2021

Tags: Astra Zeneca, vaccine, vaccine candidates, COVID-19,

Source: https://apps.who.int/iris/bitstream/hand

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Greinacher, A., et al. (2021) CC

New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840

Tags: Astra Zeneca, side effects, thrombocytopenic disorder, covid-19, Vaccination,

Source: https://www.nejm.org/doi/full/10.1056/NE

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

European Medicines Agency EMA (2021) CC

7 April 2021

Tags: Astra Zeneca, side effects, blood clots, vaccine, COVID-19,

Source: https://www.ema.europa.eu/en/news/astraz

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 mRNA-1273 de Moderna

Organisation Mondiale de la Santé OMS (2021) C_WHO

Ces orientations provisoires ont été élaborées sur la base de l’avis émis par le Groupe stratégique consultatif d’experts (SAGE) sur la vaccination lors de sa réunion extraordinaire du 21 janvier 2021

Tags: Moderna, vaccine, COVID-19, mRNA, OMS,

Source: https://apps.who.int/iris/bitstream/hand

	Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm, 7 May 2021 World Health Organization WHO (2021) C_WHO View PDF(2) Download (2) Add to my MEDBOX 7 May 2021 Tags: sinopharm, vaccine, COVID-19, SARS-CoV-2, vaccine candidates, inactivated vaccines, Source: https://apps.who.int/iris/rest/bitstream
	Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (Arabic) World Health Organization WHO (2021) C_WHO View PDF(3) Download (2) Add to my MEDBOX Interim guidance, 7 May 2021 Tags: sinopharm, vaccine, COVID-19, SARS-CoV-2, vaccine candidates, inactivated vaccines, Source: https://apps.who.int/iris/bitstream/hand
	Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables World Health Organization WHO (2021) C_WHO View PDF(2) Download (5) Add to my MEDBOX 1 June 2021 Tags: sinovac, COVID-19, vaccine, SARS-CoV-2, Source: https://apps.who.int/iris/rest/bitstream
	Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older CDC (2021) CC View PDF(2) Download (5) Add to my MEDBOX These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older Tags: vaccine, Moderna, COVID-19, Source: https://www.cdc.gov/vaccines/covid-19/in
	AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine World Health Organization WHO (2021) C_WHO View PDF(6) Download (8) Add to my MEDBOX 10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks Tags: Astra Zeneca, vaccine, vaccine candidates, side effects, clinical trials, COVID-19, SARS-CoV-2, Source: https://www.who.int/docs/default-source/
	COVID-19 & Vaccination Mauder, S. (2021) CC View PDF(190) Download (102) Add to my MEDBOX Issue Brief no.8. January 18,2021 Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies, implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages Tags: Vaccination, Access, strategy, Immunization, Guidelines, global initiatives, vaccine candidates, research, vaccine trial, resources, Source: https://medbox.org/document/covid-19-vac
	Orientations provisoires pour l’utilisation du vaccin anti-COVID-19 AZD1222 (‎ChAdOx1-S [‎recombinant]‎)‎ développé par l’Université d’Oxford et AstraZeneca Organisation Mondiale de la Santé OMS (2021) C_WHO View PDF(2) Download (5) Add to my MEDBOX 10 février 2021 Tags: Astra Zeneca, vaccine, vaccine candidates, COVID-19, Source: https://apps.who.int/iris/bitstream/hand
	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Greinacher, A., et al. (2021) CC Open external link (152) Add to my MEDBOX New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840 Tags: Astra Zeneca, side effects, thrombocytopenic disorder, covid-19, Vaccination, Source: https://www.nejm.org/doi/full/10.1056/NE
	AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets European Medicines Agency EMA (2021) CC Open external link (200) Add to my MEDBOX 7 April 2021 Tags: Astra Zeneca, side effects, blood clots, vaccine, COVID-19, Source: https://www.ema.europa.eu/en/news/astraz
	Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 mRNA-1273 de Moderna Organisation Mondiale de la Santé OMS (2021) C_WHO View PDF(2) Download (7) Add to my MEDBOX Ces orientations provisoires ont été élaborées sur la base de l’avis émis par le Groupe stratégique consultatif d’experts (SAGE) sur la vaccination lors de sa réunion extraordinaire du 21 janvier 2021 Tags: Moderna, vaccine, COVID-19, mRNA, OMS, Source: https://apps.who.int/iris/bitstream/hand

About MEDBOX

MEDBOX Video Series